Sign in
HLVX Stock Price, Chart, Stats & News
HilleVax, Inc.
Save
104.76M
Market cap
–
Current P/E
–
Forward P/E
HLVX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -40.65% |
ROE | -44.61% |
D/E | 0.16x |
Interest coverage ratio | -41.62x |
HLVX valuation
P/E | – |
P/S | – |
P/B | 0.71x |
P/CF | -1.76x |
P/FCF | -1.71x |
P/OCF | -1.76x |
PEG | -0.04x |
EV multiple | -2.10x |
About
HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.
Similar securities
Based on sector and market capitalization
Report issue